tbuckley/cabot-search huggingface dataset:
Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC).
Authors: Thomas E. Hutson, Corina E. Dutcus, Min Ren, Mahadi Ali Baig, Mayer N. Fishman
Journal: Journal of Clinical Oncology (2016)

4553 Background: In the randomized phase 2 study of LEN, EVE, and LEN+EVE in mRCC, LEN+EVE significantly improved the primary endpoint median progression-free survival (PFS) vs EVE (14.6 vs 5.5 months [mos]; hazard ratio [HR] 0.40; 95% confidence interval [CI] 0.24–0.68; P= 0.0005). LEN alone (7.4 mos) also improved median PFS vs EVE (HR 0.61; 95% CI 0.38–0.98; P= 0.048). We report PFS outcomes by patient subgroups. Methods: Patients with progressive clear cell mRCC following 1 VEGF-targeted therapy received LEN (24 mg/d), EVE (10 mg/d), or LEN+EVE (18+5 mg/d). Exploratory subgroups included baseline tumor size (sum of tumor diameters), Memorial Sloan-Kettering Cancer Center (MSKCC) risk group, and metastasis site. The data cutoff for the primary analysis was June 13, 2014; updated cutoff (for overall survival [OS] only) was July 31, 2015. Results: Median PFS was improved in LEN+EVE vs EVE in all examined subgroups (Table). In an updated analysis of OS, the median was 25.5 mos (95% CI 16.4–32.1), 19.1 mos (95% CI 13.6–26.2), and 15.4 mos (95% CI 11.8–20.6) for LEN+EVE, LEN, and EVE, respectively. In comparison with EVE, overall survival was longer for LEN+EVE, a trend that was maintained through the cutoff for the updated OS analysis (HR 0.59; 95% CI 0.36–0.96; P= 0.065). Notably, the HR remains < 0.6, and the upper limit of the CI no longer crosses 1. Conclusions: The PFS advantage with LEN+EVE vs EVE was maintained in all examined subgroups. The updated OS analysis demonstrated a trend towards survival benefit with LEN+EVE vs EVE in patients with mRCC following 1 VEGF-targeted therapy. Clinical trial information: NCT 01136733. Median PFS, mos HR (95% CI); P-value (LEN+EVE vs EVE) n LEN n = 52 n LEN+EVE n = 51 n EVE n = 50 MSKCC risk Favorable 11 18.4 12 20.1 12 9.8 0.25 (0.08–0.76); P = 0.009 Intermediate 18 7.2 19 14.6 19 5.5 0.35 (0.15–0.80); P = 0.0243 Poor 23 5.6 20 5.6 19 3.5 0.44 (0.20–0.98); P = 0.0936 Baseline tumor size < Median 27 7.4 24 14.7 25 5.5 0.34 (0.16–0.71); P = 0.0035 ≥ Median 25 7.2 27 11.2 25 5.3 0.39 (0.19–0.80); P = 0.0134 Metastasis site Bone 23 7.2 16 5.4 17 3.6 0.41 (0.18–0.94) Visceral organs 49 7.4 41 9.5 44 5.5 0.44 (0.26–0.77) Lymph nodes 32 8.0 29 14.7 31 5.5 0.28 (0.14–0.58)
Abstract 99: IL10-inhibits Fibroblast Progenitor Cell-mediated Cardiac Fibrosis in Pressure-overloaded Myocardium
Authors: Suresh K Verma, Venkata N Garikipati, Prasanna Krishnamurthy, Cindy Benedict, Emily Nickoloff, Raj Kishore
Journal: Circulation Research (2016)

Background: Activated fibroblasts (myoFBs) play critical role in cardiac fibrosis, however, their origin in diseased heart remains uncertain. Recent studies suggest the contribution of bone marrow fibroblasts progenitor cells (BM-FPC) in pressure overload (PO)-induced cardiac fibrosis. Previously we have shown that interleukin-10 suppress PO-induced cardiac fibrosis, however, its role on inhibition of BM-FPC-mediated fibrosis is not known. Thus, we hypothesized that IL-10 inhibits PO-induced homing and transition of BM-FPC to myoFBs and therefore, attenuates cardiac fibrosis. Methods and Results: Cardiac fibrosis was induced in Wild-type (WT) and IL-10-knockout (KO) mice by transverse aortic constriction (TAC). TAC-induced left ventricular (LV) dysfunction and fibrosis were further exaggerated in KO mice. Systemic recombinant IL-10 administration markedly improved LV function and inhibited PO-induced cardiac fibrosis. PO-enhanced FPC (Prominin1 + cells) mobilization and homing in IL-10 KO mice compared to WT mice. Furthermore, bone marrow transplantation (BMT) experiment was performed wherein WT marrow from GFP mice was repopulated in IL-10 KO mice. FPC mobilization was significantly reduced in BMT-IL10 KO mice compared to IL-10 KO mice after TAC. Furthermore, immunofluorescence result in BMT mice showed that subsets of myoFBs are derived from BM after TAC. To identify the molecular mechanism, wild type BM-FPC were treated with TGFβ 2 with or without IL10. IL10 treatment significantly inhibits TGFβ 2 -induced FPC to myoFBs transition. As miRNAs are key players in cardiac fibrosis, next we performed fibrosis-associated miRNA profiling using miRNA array kit. TGFβ 2 -induced miR-208, 155, 21 and 145 expression was markedly inhibited by IL-10. Conclusion: Taken together, our findings suggest that both reduced homing to heart and transition of FPC to myofibroblasts mediate anti-fibrotic effect of IL10 during PO-induced heart failure. Ongoing investigations using molecular approaches will provide a better understanding on the mechanistic and therapeutic aspects of IL10 on PO-induced cardiac fibrosis and heart failure.
Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
Authors: Mohamed Bouattour, Eric Raymond, Shukui Qin, Ann‐Lii Cheng, Uz Stammberger, Giuseppe Locatelli, Sandrine Faivre
Journal: Hepatology (2017)

Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c‐Met inhibition may have therapeutic potential. However, clinical trials of nonselective kinase inhibitors with c‐Met activity (tivantinib, cabozantinib, foretinib, and golvatinib) in patients with HCC have failed so far to demonstrate significant efficacy. This lack of observed efficacy is likely due to several factors, including trial design, lack of patient selection according to tumor c‐Met status, and the prevalent off‐target activity of these agents, which may indicate that c‐Met inhibition is incomplete. In contrast, selective c‐Met inhibitors (tepotinib, capmatinib) can be dosed at a level predicted to achieve complete inhibition of tumor c‐Met activity. Moreover, results from early trials can be used to optimize the design of clinical trials of these agents. Preliminary results suggest that selective c‐Met inhibitors have antitumor activity in HCC, with acceptable safety and tolerability in patients with Child‐Pugh A liver function. Ongoing trials have been designed to assess the efficacy and safety of selective c‐Met inhibition compared with standard therapy in patients with HCC that were selected based on tumor c‐Met status. Thus, c‐Met inhibition continues to be an active area of research in HCC, with well‐designed trials in progress to investigate the benefit of selective c‐Met inhibitors. (H epatology 2018;67:1132–1149)
The Liver Catalase Activity of Tumor-Bearing Mice and the Effect of Spontaneous Regression and of Removal of Certain Tumors
Authors: Jesse P. Greenstein, Howard B. Andervont
Journal: JNCI Journal of the National Cancer Institute (1942)

Journal Article The Liver Catalase Activity of Tumor-Bearing Mice and the Effect of Spontaneous Regression and of Removal of Certain Tumors Get access Jesse P. Greenstein, Jesse P. Greenstein research fellow Search for other works by this author on: Oxford Academic PubMed Google Scholar Howard B. Andervont Howard B. Andervont principal biologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 4, February 1942, Pages 345–355, https://doi.org/10.1093/jnci/2.4.345 Published: 01 February 1942
ROC Cutpoints May Help Clinicians Predict the Need for Pacemakers Prior to TAVR
Authors: Kenechukwu Mezue, Janani Rangaswami, Alexandra Tuluca, Christian Witzke
Journal: JACC. Cardiovascular imaging (2017)

Pacemaker implantations following transcatheter aortic valve replacement are relatively common, occurring in up to 1 in 6 procedures, and this has been associated with increased mortality and rehospitalizations [(1)][1]. The recent paper by Maeno et al. [(2)][2] found that right bundle branch block
NCCN-IPI in Patients with Diffuse Large B CELL Lymphoma Treated with DA-R-EPOCH. Retrospective Analysis
Authors: Juan Miguel Bergua Burgues, Luis Lopez-Gomez, Fatima Ibañez, Sara Suarez-Varela, Julio Prieto-Fernandez, Fernando Carnicero, Ignacio Casas, Maria Luisa Martín-Mateos, Carmen Cabrera, María José Arcos-Carmona, M Helena Bañas, Nuria Bermejo, Miguel A. Sanz, Sara Bobillo-Varela, Andres Lopez
Journal: Blood (2016)
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol
Authors: E. Bernichon, A. Vallard, Q. Wang, V. Attignon, D. Pissaloux, T. Bachelot, P.E. Heudel, I. Ray-Coquard, E. Bonnet, A. de la Fouchardière, C. Faure, N. Chopin, F. Beurrier, S. Racadot, M.P. Sunyach, C. Rancoule, D. Perol, V. Corset, V. Agrapart, F. Tinquaut, J.-Y. Blay, N. Magné, O. Trédan
Journal: Annals of Oncology (2017)
Association of Intraoperative Radiotherapy in the Treatment of Early-Stage Breast Cancer With Minor Surgical Site Complications in Oncoplastic Breast-Conserving Surgery
Authors: Angelena Crown, Janie W. Grumley
Journal: JAMA Surgery (2017)

This case-control study compares the surgical site complications associated with oncoplastic breast surgery with intraoperative radiotherapy and oncoplastic breast surgery with whole-breast radiotherapy within 6 months of surgery.
Pancreatoblastoma With Metastatic Retroperitoneal Lymph Node and PET/CT
Authors: Giuseppe Corrias, Monica Ragucci, Olca Basturk, Luca Saba, Lorenzo Mannelli
Journal: Clinical Nuclear Medicine (2017)

A previously healthy 4-year-old girl presented with petechial rash and low platelet count. There were no other symptoms. On abdominal ultrasound, a 4.7-cm heterogeneous mass was demonstrated anterior to the left kidney. An abdominal MRI subsequently performed demonstrated a heterogeneously enhancing mass at the same location extending to the pancreas and spleen. A surgical biopsy of the mass was obtained. Pathology reported a malignant epithelioid neoplasm consistent with pancreatoblastoma. The mass demonstrated intense FDG uptake on PET and an FDG avid retrocaval lymph node.
Note on the Composition of the Nucleoprotein Fraction of Normal Liver and of the Transplanted Hepatic Tumor in the Rat
Authors: Jesse P. Greenstein, Wendell V. Jenrette, Julius White
Journal: JNCI Journal of the National Cancer Institute (1941)

Note on the Composition of the Nucleoprotein Fraction of Normal Liver and of the Transplanted Hepatic Tumor in the Rat Get access Jesse P. Greenstein, Jesse P. Greenstein research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Wendell V. Jenrette, Wendell V. Jenrette junior physiologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Julius White Julius White research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 3, December 1941, Pages 305–306, https://doi.org/10.1093/jnci/2.3.305 Published: 01 December 1941
Medical Students Fall Short on Blood Pressure Check Challenge
Authors: Jennifer Abbasi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
効率的化学療法のためのフェニルボロン酸をベースにした低分子量ゲルのその場注入【Powered by NICT】
Authors: Gao Wenxia, Liang Yan, Peng Xinyu, Hu Yalong, Zhang Longgui, Wu Huayue, He Bin
Journal: Biomaterials (2016)
Pml Nuclear Body Disruption Cooperates in APL Pathogenesis, Impacting DNA Damage Repair Pathways
Authors: Edwige Voisset, Eva Moravcsik, Eva W Stratford, Amie Jaye, Christopher J Palgrave, Robert K Hills, Paolo Salomoni, Scott C. Kogan, Ellen Solomon, David Grimwade
Journal: Blood (2016)
Estimated Effects of Future Atmospheric CO2 Concentrations on Protein Intake and the Risk of Protein Deficiency by Country and Region
Authors: Danielle E. Medek, Joel Schwartz, Samuel S. Myers
Journal: Environmental Health Perspectives (2017)

Background: Crops grown under elevated atmospheric CO2 concentrations (eCO2) contain less protein. Crops particularly affected include rice and wheat, which are primary sources of dietary protein for many countries. Objectives: We aimed to estimate global and country-specific risks of protein deficiency attributable to anthropogenic CO2 emissions by 2050. Methods: To model per capita protein intake in countries around the world under eCO2, we first established the effect size of eCO2 on the protein concentration of edible portions of crops by performing a meta-analysis of published literature. We then estimated per-country protein intake under current and anticipated future eCO2 using global food balance sheets (FBS). We modeled protein intake distributions within countries using Gini coefficients, and we estimated those at risk of deficiency from estimated average protein requirements (EAR) weighted by population age structure. Results: Under eCO2, rice, wheat, barley, and potato protein contents decreased by 7.6%, 7.8%, 14.1%, and 6.4%, respectively. Consequently, 18 countries may lose >5% of their dietary protein, including India (5.3%). By 2050, assuming today's diets and levels of income inequality, an additional 1.6% or 148.4 million of the world's population may be placed at risk of protein deficiency because of eCO2. In India, an additional 53 million people may become at risk. Conclusions: Anthropogenic CO2 emissions threaten the adequacy of protein intake worldwide. Elevated atmospheric CO2 may widen the disparity in protein intake within countries, with plant-based diets being the most vulnerable. https://doi.org/10.1289/EHP41
Intensive Blood Pressure Control on Gait Speed and Mobility Limitation for Older Adults—Reply
Authors: Michelle C. Odden, Jeff D. Williamson, Nicholas M. Pajewski
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
角膜炎症の治療のための結膜下注射可能なデンドリマデキサメタゾンゲル【Powered by NICT】
Authors: Soiberman Uri, P Kambhampati Siva, Wu Tony, K Mishra Manoj, Oh Yumin, Sharma Rishi, Wang Jiangxia, Al Towerki Abdul Elah, Yiu Samuel, J Stark Walter, M Kannan Rangaramanujam
Journal: Biomaterials (2017)
健康成人の血流におけるオメガ‐3脂肪酸,ドコサヘキサエン酸とエイコサペンタエン酸の世界的調査【Powered by NICT】
Authors: D Stark Ken, E Van Elswyk Mary, Higgins M. Roberta, A Weatherford Charli, Salem Norman
Journal: Progress in Lipid Research (2016)
Microglia in Alzheimer’s disease
Authors: Heela Sarlus, Michael T. Heneka
Journal: Journal of Clinical Investigation (2017)

Microglia are brain-resident myeloid cells that mediate key functions to support the CNS. Microglia express a wide range of receptors that act as molecular sensors, which recognize exogenous or endogenous CNS insults and initiate an immune response. In addition to their classical immune cell function, microglia act as guardians of the brain by promoting phagocytic clearance and providing trophic support to ensure tissue repair and maintain cerebral homeostasis. Conditions associated with loss of homeostasis or tissue changes induce several dynamic microglial processes, including changes of cellular morphology, surface phenotype, secretory mediators, and proliferative responses (referred to as an "activated state"). Activated microglia represent a common pathological feature of several neurodegenerative diseases, including Alzheimer's disease (AD). Cumulative evidence suggests that microglial inflammatory activity in AD is increased while microglial-mediated clearance mechanisms are compromised. Microglia are perpetually engaged in a mutual interaction with the surrounding environment in CNS; thus, diverse microglial reactions at different disease stages may open new avenues for therapeutic intervention and modification of inflammatory activities. In this Review, the role of microglia in the pathogenesis of AD and the modulation of microglia activity as a therapeutic modality will be discussed.
Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study
Authors: Brendon P Scicluna, Lonneke A van Vught, Aeilko H Zwinderman, Maryse A Wiewel, Emma E Davenport, Katie L Burnham, Peter Nürnberg, Marcus J Schultz, Janneke Horn, Olaf L Cremer, Marc J Bonten, Charles J Hinds, Hector R Wong, Julian C Knight, Tom van der Poll, Friso M. de Beer, Lieuwe D.J. Bos, Jos F. Frencken, Maria E. Koster-Brouwer, Kirsten van de Groep, Diana M. Verboom, Gerie J. Glas, Roosmarijn T.M. van Hooijdonk, Arie J. Hoogendijk, Mischa A. Huson, Peter M. Klein Klouwenberg, David S.Y. Ong, Laura R.A. Schouten, Marleen Straat, Esther Witteveen, Luuk Wieske
Journal: The Lancet Respiratory Medicine (2017)
The Early Stages of Carcinogenesis by 20-Methylcholanthrene in the Skin of the Mouse. II. Microscopic Tissue Changes&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: W. Cramer, R. E. Stowell
Journal: JNCI Journal of the National Cancer Institute (1942)

Journal Article The Early Stages of Carcinogenesis by 20-Methylcholanthrene in the Skin of the Mouse. II. Microscopic Tissue Changes Get access W. Cramer, W. Cramer research associate, research associate in cytology Barnard Free Skin and Cancer Hospital, and Washington University, St. Louis Search for other works by this author on: Oxford Academic PubMed Google Scholar R. E. Stowell R. E. Stowell research fellow Barnard Free Skin and Cancer Hospital, and Washington University, St. Louis Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 4, February 1942, Pages 379–402, https://doi.org/10.1093/jnci/2.4.379 Published: 01 February 1942
Personal Care Product Use in Men and Urinary Concentrations of Select Phthalate Metabolites and Parabens: Results from the Environment And Reproductive Health (EARTH) Study
Authors: Feiby L. Nassan, Brent A. Coull, Audrey J. Gaskins, Michelle A. Williams, Niels E. Skakkebaek, Jennifer B. Ford, Xiaoyun Ye, Antonia M. Calafat, Joseph M. Braun, Russ Hauser
Journal: Environmental Health Perspectives (2017)

Background: Personal care products (PCPs) are exposure sources to phthalates and parabens; however, their contribution to men's exposure is understudied. Objectives: We examined the association between PCP use and urinary concentrations of phthalate metabolites and parabens in men. Methods: In a prospective cohort, at multiple study visits, men self-reported their use of 14 PCPs and provided a urine sample (2004–2015, Boston, MA). We measured urinary concentrations of 9 phthalate metabolites and methylparaben, propylparaben, and butylparaben. We estimated the covariate-adjusted percent change in urinary concentrations associated with PCP use using linear mixed and Tobit mixed regressions. We also estimated weights for each PCP in a weighted binary score regression and modeled the resulting composite weighted PCP use. Results: Four hundred men contributed 1,037 urine samples (mean of 3/man). The largest percent increase in monoethyl phthalate (MEP) was associated with use of cologne/perfume (83%, p-value<0.01) and deodorant (74%, p-value<0.01). In contrast, the largest percent increase for parabens was associated with the use of suntan/sunblock lotion (66–156%) and hand/body lotion (79–147%). Increases in MEP and parabens were generally greater with PCP use within 6 h of urine collection. A subset of 10 PCPs that were used within 6 h of urine collection contributed to at least 70% of the weighted score and predicted a 254–1,333% increase in MEP and parabens concentrations. Associations between PCP use and concentrations of the other phthalate metabolites were not statistically significant. Conclusions: We identified 10 PCPs of relevance and demonstrated that their use within 6 h of urine collection strongly predicted MEP and paraben urinary concentrations. https://doi.org/10.1289/EHP1374
Depression and outcome in acute myocardial infarction:: Author's reply
Authors: P. Silverstone
Journal: BMJ (1987)

With regard to the comments of Dr R Ahmad and coworkers (7 February, p 372) it is interesting that their patients undergoing carpal tunnel release did not have arthropathy affecting large joints.This suggests that the carpal tunnel syndrome, though often seen in association with the arthro- pathy that affects large joints, may have a different pathogenesis.It is therefore perhaps not surprising that synovial iron deposits were rare in their patients.Amyloid deposits may be a factor in the carpal tunnel syndromes, and some patients with amyloidosis associated with plasma cell dyscrasias are known to develop this complication.